Karen Jean Ferrante
CIK 1598502 · Head Res. & Dev. & Chief Med. · last filed 2026-06-11
Karen Jean Ferrante is a Head Res. & Dev. & Chief Med. who has filed 63 SEC Form 4 insider transactions across 6 companies since 2014. The most recent filing, for COGT, was dated Jun 11, 2026. Current disclosed insider exposure totals $58.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$58.4K
6
63
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COGT | Director | — | $33.10 | — | $0 | 28 | 2026-06-11 |
| MGNX | Director | 14,750 | $3.96 | $58.4K | $0 | 12 | 2026-05-20 |
| Cogent Biosciences, Inc. (UMRX) Delisted | Director | — | — | — | $0 | 12 | 2020-10-02 |
| PROGENICS PHARMACEUTICALS INC (PGNX) Delisted | Director | — | — | — | $0 | 6 | 2019-07-15 |
| Baxalta Inc (BXLT) Delisted | Director | 7,657 | — | — | $0 | 2 | 2016-05-12 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Head Res. & Dev. & Chief Med. | — | — | — | $0 | 1 | 2015-12-17 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | COGT | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | MGNX | Mixed | +3,750 | $0 | EDGAR |
| 2026-04-03 | COGT | Grant (A) | — | $0 | EDGAR |
| 2026-01-05 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-10-03 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | MGNX | Mixed | +6,500 | $0 | EDGAR |
| 2025-04-03 | COGT | Grant (A) | — | $0 | EDGAR |
| 2025-01-03 | COGT | Grant (A) | — | $0 | EDGAR |